research Efficacy and Safety of Topical Calcipotriol in Management of Alopecia Areata: A Pilot Study
Topical calcipotriol may help treat alopecia areata, especially in those with low vitamin D.
Search
for
Sort by
Research
30 / 62 results
research Efficacy, Safety, and Pharmacoeconomics of Three Common Strategies for Pediatric Alopecia Areata Patients: A Retrospective Cohort Study
Traditional treatment for pediatric alopecia areata is most effective and should be first choice.
research Treatment of Severe Alopecia Areata with Oral Tofacitinib: A Case Series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research Oral Janus Kinase Inhibitors for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Characterization of Scalp, Eyelash, and Eyebrow Hair Regrowth in Patients with Severe Alopecia Areata Randomized to Placebo in BRAVE AA1 and BRAVE AA2 Trials
Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
research Response to Ritlecitinib Treatment Based on Salt Improvement Scores in Patients With Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research Sublingual Tofacitinib for Alopecia Areata: A Roll-Over Pilot Clinical Trial and Analysis of Pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Treatment of Alopecia Areata: An Australian Expert Consensus Statement
Alopecia areata treatment varies, with no optimal method established yet.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
research Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis
Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
research Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series
Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
research Systemic Treatments for Alopecia Areata: A Systematic Review
No systemic treatment for alopecia areata has strong evidence of effectiveness.
research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata
1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research The Use of Phosphodiesterase Inhibitors for the Treatment of Alopecia
Caffeine shows promise for treating some types of hair loss, but more research is needed.
research Correlation Between Serum Granulysin Level and Clinical Activity in Patients with Alopecia Areata Before and After Tofacitinib Therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Cytokine-Targeted Treatment in Alopecia Areata - New Possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.